Skip to main content


Big Time Vasculitis (3.10.2023)

Mar 10, 2023

Dr. Jack Cush Reviews the News and Journal articles from the past week on RheumNow. This weeks highlights includes insights on scleroderma, myositis, vasculitis and answers the question - does aggressive biologic treatment of psoriasis prevent future psoriatic arthritis?

Read Article
Differential Dx of Granulomatous Myopathy: Sarcoidosis, inclusion-body myositis, myasthenia gravis, Crohns, GPA, TB, brucellosis, syphilis, PBC, RA, systemic sclerosis , lymphoma, checkpoint inhibitors, GVHD, natural killer/T-cell lymphoma
Does Methotrexate Increase Skin Cancer Risk? A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.
Does Methotrexate Increase Skin Cancer Risk? A report from the British Journal of Cancer has also shown an increased risk of basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC) with MTX use; and more so with higher doses.

Does Methotrexate Increase Skin Cancer Risk?

Feb 09, 2023

There are several reports suggesting a link between methotrexate (MTX) use and certain skin cancers, yet these are confounded by a higher risk of skin cancers with inflammatory conditions like rheumatoid arthritis of which MTX is the most common treatment. A report from the British

Read Article

Simon Says “Don’t Do This” (1.27.2022)

Jan 27, 2023

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

  1. "Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs

Read Article
Cancer Risk with Scleroderma Spanish Scleroderma Registry examined a large cohort of systemic sclerosis (SSc) patients showing an increased cancer risk, especially breast, lung, hematologic and colorectal cancer. #BestOf2022

Xeljanz Cancer Risks Detailed

MedPage Today
Dec 07, 2022

The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.

Tofacitinib at either 5 or 10 mg twice daily in the so-called ORAL

Read Article

Cancer Screening Recommendations in Idiopathic Inflammatory Myopathy

Nov 28, 2022

Idiopathic inflammatory myopathy (IIM) is associated with increased risk of lung, ovarian, colorectal, lymphoma, breast, and naso-pharyngeal cancers, often within three years of disease onset. At ACR22, plenary abstract 0002, Oldroyd, et al, reviewed the 18 recommendations provided by the

Read Article
Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254

ACR 2022 - Day 1 Report

Nov 13, 2022

The masses have returned to ACR22, a live, face-to-face, and virtual, meeting that began Saturday in Philadelphia. There were hassles and glitches, yet the education and sessions were as you’d expect with many good presentations worth recapping.

Read Article

Updates on Reproductive Health in Women with SLE

Nov 12, 2022

Is patient-administered cervical cancer screening an option for women with SLE? Should I prescribe estrogen containing contraceptives to SLE women with APL antibodies? What complications should I be aware of in pregnant women with SLE? Here are three abstracts that provide insight.

Read Article
BIOBADASAR study of cancer risk in RA patients with prev cancer treated with b/tsDMARD. No increased risk, but yet again abatacept numbers are making me slightly nervous! @rheumnow #ACR22 Abstr#0267
Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow
#ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow
Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis
Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis
Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis
Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary
Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy 🔸Ovarian cancer - most common Really important to do cancer screening in #dermatomyositis #ACR22 @RheumNow

Avoid Abatacept in RA patients with a history of cancer?

The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of

Read Article
Did You Know? FDA relaxed warnings on #sarcoma with #Forteo- can use more than 2 years ⁦@RheumNow⁩ #acr22 #acrreview #osteoporosis

Women with Rheumatic Disease (11.4.2022)

Nov 04, 2022

Dr. Jack Cush reviews the news and journal articles from this past week on  New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes?

  1. Population study shows among vaccinated gout pts, COVID breakthrough

Read Article

2022 CDC Clinical Practice Guideline on Opioid Prescribing

Nov 03, 2022

The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute (duration of <1 month), subacute (duration of 1–3 months), and chronic (duration of >3 months) pain.

This guideline provides recommendations for clinicians

Read Article